CTMX CytomX Therapeutics, Inc.
$3.29▼ -1.79%
Healthcare
Other
After hours
$3.30▲ +0.30%
Sep 11, 7:59 PM ET
Volume 2.25M
Avg Volume (10D) 3.34M
Key Metrics & Fundamentals
Market Cap
$716.89M
P/E Ratio
–
Div Yield
–%
52W Range
1.90 - 8.21
% vs 50 MA
-5.20%
% vs 200 MA
-20.74%
RSI-14
43.6
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.70
Free Cash Flow
-$18.07M
Gross Rev
$1.42M
Gross Profit
$1.42M
EBITDA
-$23.73M
COGS
–
Operating Exp
$25.20M
Operating Income
-$23.78M
EBIT
-$23.78M
Pretax Income
-$20.61M
Net Income
-$20.67M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
CytomX Therapeutics to Present at Upcoming September Investor Conferences
GlobeNewswire · Sep 1, 2026 12:00 PM
CytomX's Varseta-M Receives FDA Fast-Track Designation to Treat Colorectal Cancer
MT Newswires · Aug 27, 2026 12:54 PM
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)
GlobeNewswire · Aug 27, 2026 12:00 PM
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
GuruFocus.com · Aug 7, 2026 5:03 AM
CytomX Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 1:03 AM
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 6, 2026 11:10 PM
CytomX Therapeutics: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 9:04 PM
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 8:15 PM
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 8:15 PM
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer
GlobeNewswire · Aug 3, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See CTMX's money flow as a full page
Social Sentiment
No Reddit posts found for CTMX.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.